Differential pleiotropy is observed for the HD containing Drosophila, Human and yeast TFs: Ultrabithorax, Fushi tarazu, Sex combs reduced, Antennapedia, HOXA7
, HOXB3, and Pho2p; therefore, in order to make a more general statement, observation of differential pleiotropy needs to be extended to other TF families.
HOXA7. Hoxa7 knockout mice showed reduced megakaryocytic/erythroid progenitors (MEP) and exhibited reticulocytosis and thrombocytopenia without anemia , suggesting that HOXA7 is required for MEP differentiation.
Cleary, "Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9," Blood, vol.
Gene Fold change NCBI access HOXA9 2.24 NM_152739.3 HOXC5 2.69 NM_018953.2 HOXD4 2.78 NM_014621.2 HOXD1 2.36 NM_024501.1 HOXB13 14.62 NM_006361.5 HOXA5 2.05 NM_019102.1 HOXC10 6.19 NM_017409.3 HOXC6 4.42 NM_004503.3 HOXB7 2.22 NM_004502.3 HOXB9 20.59 NM_024017.3 HOXA7
2.54 NM_006896.3 HOXC11 2.09 NM_014212.3 HOXA10 4.08 NM_018951.2 HOXD13 16.47 NM_000523.3 HOXC8 2.89 NM_022658.3 Table 2: Correlation of HOXB9, HOXB13, and HOXD13 genes expression levels with clinicopathological variables in LSCC patients (n = 168).
glioblastoma Squamous cell TarBase HOXA7
, TMED7, NF2, CUL4B, PPP1R7, et al.
This gene repression profile, in the form of H3K27-trimethylation, was mediated by Polycomb-group (PcG) proteins over genes such as SOX9, HOXA7
, WNT5b, FGF18, and LGR5.
miRNAs downregulated in chemoresistance to conventional drugs miR-22 5-FU BTG1 miR-34a 5-FU SIRT1, E2F3, KIT, LDHA miR-122 5-FU PKM2 miR-129 5-FU BCL2, TYMS, E2F3 miR-133a Oxaliplatin RFFL miR-139-5p 5-FU NOTCH1 miR-141/200c Oxaliplatin ZEB1 miR-143 5-FU, oxaliplatin BCL2, NFKB, ERK5, IGF1R miR-145 5-FU FLI-1, RAD18 miR-149 5-FU FOXM1 miR-153 Oxaliplatin FOXO3 miR-196a Oxaliplatin HOXA7
, HOXB8, HOXC8, HOXD8 miR-200 cluster 5-FU EMT-related genes miR-203 5-FU TYMS miR-204 5-FU HMGA2 miR-222 Oxaliplatin ADAM17 miR-297 Oxaliplatin ABCC2 miR-451 Irinotecan ABCC1 miR-497 5-FU, irinotecan IGF1R miR-519c 5-FU, oxaliplatin ABCG2, ELAVL1 (HuR) miR-1915 Oxaliplatin BCL2 miRNAs overexpressed in chemoresistance to monoclonal antibody-based therapies miR-17-3p Cetuximab ?